Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
5(100.0%)
5Total
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06890897Not ApplicableRecruiting

Esketamine Combined Pulsed Radiofrequency for Acute/Subacute Zoster-associated Trigeminal Neuralgia

Role: collaborator

NCT06896994Not ApplicableRecruiting

Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia

Role: collaborator

NCT06914193Not ApplicableNot Yet Recruiting

Esketamine Combined With PRF of DRG for Postherpetic Neuralgia

Role: collaborator

NCT06914206Not ApplicableNot Yet Recruiting

Esketamine Combined With PRF of DRG for Acute/Subacute Zoster-associated Pain

Role: collaborator

NCT06914180Not ApplicableNot Yet Recruiting

Esketamine Combined With PRF for Trigeminal Postherpetic Neuralgia

Role: collaborator

All 5 trials loaded